<DOC>
	<DOCNO>NCT02063789</DOCNO>
	<brief_summary>Human immunoglobulin ( Ig ) commonly use blood product . It well-defined efficacy patient immunodeficiency , Kawasaki disease , asthma immune disease . It expect Ig 10 % improve usefulness safety profile compare Ig 5 % expect reduced hospitalization/treatment duration less adverse event related volume overload .</brief_summary>
	<brief_title>An Open Phase 3 Study IV-Globulin SN Inj.10 % Treat Immune Thrombocytopenia</brief_title>
	<detailed_description>GC5107A ( IV-Globulin SN Inj . 10 % ) polyvalent intravenous human immunoglobulin G preparation . It prepare plasma collected 1000 healthy blood donor express large spectrum antibody specificity .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Purpura , Thrombocytopenic , Idiopathic</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Given write informed consent Male female age â‰¥ 19 Primary immune thrombocytopenia ( ITP ) Platelet &lt; 20x10^9 /L Patients take adrenal cortical hormone and/or immunosuppressive medication maintain stable dos study Patients participate interventional study within 30 day Inability written/verbal communication Engaged elective surgery Pregnant breastfeed woman Women childbearing potential agree contraception study Patients experience hypersensitivity shock study drug active ingredient Refractory immunoglobulin therapy Secondary immune thrombocytopenia HIVassociated ITP Lupusassociated ITP Lymphproliferative disease Hepatitis virus carrier Other disease infectionassociated ITP DrugInduced ITP Hereditary thrombopenia ( e.g. , MYH9 disorder ) Hemolytic anemia ( Positive direct Coomb 's test ) Clinically significant abnormality immunoglobulin Immunoglobulin A Deficiency Immune disorder deficiency Alcohol drug abuse within 6 month Patients take medication may effect platelet function count least 2 day prior study entry Patients administrate IVIg antiD immunoglobulin agent within 1 month Patients undergone splenectomy within 2 month Clinically significant underlying disease medical history investigator 's discretion</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Immune Thrombocytopenia</keyword>
	<keyword>Immune Thrombocytopenic Purpura</keyword>
	<keyword>Idiopathic Thrombocytopenic Purpura</keyword>
	<keyword>Human Immunoglobulin</keyword>
	<keyword>ITP</keyword>
	<keyword>IVIg</keyword>
	<keyword>IgIV</keyword>
	<keyword>IV-Globulin SN Inj .</keyword>
</DOC>